[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100580773":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":25,"responsibleParty":36,"collaborators":25,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":25,"eligibilityCriteria":45,"healthyVolunteers":46,"sex":47,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":25,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":61,"whyStopped":25,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":25},{"fullName":5,"class":6},"Tanta University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group 1 (Treatment)","EXPERIMENTAL","50 patients will recieve Atomoxetine, 0.5-1.2 mg\u002Fkg\u002Fday, administered in the evening for six months.\n\nFrequency of nocturnal enuresis episodes, recorded by parents in a nightly log. ADHD symptoms, assessed using Conners-48 scores at baseline, 1, 3, and 6 months.",[13],"Drug: Atomoxetine",{"label":15,"type":10,"description":16,"interventionNames":17},"Group 2 (Control)","50 participants will receive Placebo identical in form and dosing schedule. for 6 months.\n\nFrequency of nocturnal enuresis episodes, recorded by parents in a nightly log. ADHD symptoms, assessed using Conners-48 scores at baseline, 1, 3, and 6 months.",[18],"Drug: Placebo",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Atomoxetine","Atomoxetine, 0.5-1.2 mg\u002Fkg\u002Fday, administered in the evening for six months.",[9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Placebo","Placebo identical in form and dosing schedule for six months.",[15],[31],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Osama Ibrahim Younes","CONTACT","01024188789","osamaebrahim2012@gmail.com",{"type":37,"investigatorFullName":32,"investigatorTitle":38,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","lecturer of psychiatry","100580773","early-phase-1-evaluating-the-efficacy-of-atomoxetine-in-reducing-primary-nocturnal-enuresis-in-children-with-adhd-a-randomized-placebo-controlled-study-100580773",false,"NCT06841666","Evaluating the Efficacy of Atomoxetine in Reducing Primary Nocturnal Enuresis in Children With ADHD: A Randomized, Placebo-Controlled Study","Evaluating the Efficacy of Atomoxetine in Reducing Primary Nocturnal Enuresis in Children With ADHD","Inclusion Criteria:\n\n* Children aged 6-12 years diagnosed with ADHD per Conners-48 scale. Children experiencing primary nocturnal enuresis.\n\nExclusion Criteria:\n\n* Secondary causes of enuresis (e.g., urinary tract infections, diabetes). Use of other enuresis treatments. Known contraindications to atomoxetine.",true,"ALL","6 Years","12 Years",{"count":51,"type":52},100,"ESTIMATED","INTERVENTIONAL",[55],"EARLY_PHASE1","1. Primary Aim: To evaluate the efficacy of atomoxetine in reducing the frequency of primary nocturnal enuresis episodes in children with ADHD.\n2. Secondary Aim: To determine if improvements in attention symptoms correlate with reductions in nocturnal enuresis episodes.",[58,59],"ADHD","Primary Nocturnal Enuresis",[59,58,22],"NOT_YET_RECRUITING","2025-02-25",{"date":64,"type":65},"2025-02-27","ACTUAL",{"date":67,"type":52},"2025-02-28",{"date":69,"type":52},"2025-09-05",{"name":5,"class":6}]